58 | Chase Terwilliger, CBDistillery

“You can expect to see a lot of other minor cannabinoids from us here in the near future, but CBG, you know, really helps with inflammation. So it’s just more targeted than just having CBD. I believe our consumers too are somewhat of a different type of consumer, we kind of call them cannabis connoisseurs, and so they really take to new minors and love to give us feedback on them.”

— Chase Terwilliger

CBD has exploded in popularity over the past few years, and now the leading companies in the space are , 58 | Chase Terwilliger, CBDistillerybeginning to emerge. CBDistillery is among those who have grown a fan base by listening to consumers and providing certified, high-quality products. We chat with CEO Chase Terwilliger  about:

  • Why a wave of clinical studies is the next chapter of CBD
  • The growing excitement around the so-called ‘minor’ cannabinoids
  • Why it’s a challenge to get CBD dosing right, and the basic dose CBDistillery recommends for most customers
  • How to get 15% off your next order at CBDistillery.com with coupon code KBOOM at checkout

Transcript of Kannaboom Podcast with Chase Terwilliger of CBDistillery

Copyright © Kannaboom Sept. 2020

Kannaboom (00:00): The CBD market has boomed in the last few years, there are so many companies providing CBD now and only a handful of them that have really committed to consumer safety. Among these is Colorado based CBDistillery. And today we're talking with their CEO, Chase Terwilliger about what's going on in this market. We discuss the differences between full spectrum, broad spectrum and isolate CBD and what CBDistillery customers prefer how to find the right dose when to expect FDA regulations to finally be enacted and about the development of new products containing the so-called minor cannabinoids like CBG. This podcast, my website Kannaboom with a k.com and my weekly newsletter 5 Boom Friday are all focused on how cannabinoids and CBD can help you achieve better wellness and how to find CBD that's trusted and reliable. You can subscribe at Apple podcasts, Stitcher, Spotify, Google podcasts, or your other favorite podcast player. And if you enjoy the show, please leave a review and help us expand our reach. And here is my interview with Chase Terwilliger.

Kannaboom (00:59): Cannabis is booming and Kannaboom is on it. Welcome to the Kannaboom podcast, where we interview experts on the changing story of humans, health and hemp. From San Diego. Here's your host, Tom Stacey. Welcome back to the podcast. Today we have Chase Terwilliger, CEO of CBDistillery. Hey, Chase. How are you doing?

Chase Terwilliger (01:18): I'm doing well, Tom. Thanks for having me.

Kannaboom (01:20): So you are in Colorado, right?

Chase Terwilliger (01:22): Correct.

Kannaboom (01:23): How is your pandemic quarantine going?

Chase Terwilliger (01:26): It's fine. I mean, we're fortunate here where we have the mountains to get away and be able to still have the social distance between each other. So, you know, it's, it's, it's been all right. And you know, they picked a good time of year, I guess. I don't know if that's the right way to say it because it's springtime here. And then early, early summer and that summer has been easy to go out and enjoy the wonderful weather and the mountains here.

Kannaboom (01:58): Some of us can be tempted to forget about the needs to just move around. And that is so huge just to get outside and be in the fresh air.

Chase Terwilliger (02:06): Absolutely. You feel normal when you're out there amongst nature, so,

Kannaboom (02:11): And you're able to keep the company going and no problems.

Chase Terwilliger (02:16): Yeah. Yeah. We haven't had too many hiccups. We're deemed an essential business. So we have manufacturing and fulfillment here right in South of Denver and that was able to stay open. Right now I'm sitting in our office in Denver and we usually have about 80 people in the office and there's five and today you know, we have kind of a soft open but everybody just continues to work from home still. And we haven't really seen any hiccups there, so we haven't, we haven't pushed the agenda, just whatever everybody's comfortable with.

Kannaboom (02:53): Yeah. So it's good. It's one of those businesses that you can keep going and serving your customers, who we've all seen. There's more of a demand than ever I think, for, for what you guys do.

Chase Terwilliger (03:05): Absolutely. Yeah. We've seen demand pick up you know, we're one of the larger e-commerce CBD companies and we've seen a pretty big pickup in demand from individuals over this time.

Kannaboom (03:17): Now you guys have been in business since 2016, correct? How did the company get started and when did you join?

Chase Terwilliger (03:25): Yeah, in mid 2016 our founder and a couple others or founder's name is Andy Papillion. He was in the cannabis industry and they actually were running a cannabis logistics business around the state. And they started seeing a demand for higher CBD strains. And then at the same time, he had a family member who came to him and said they're there, they were sick with cancer and said, 'You know, marijuana is, has been giving me health benefits tremendous benefits. But I, you know, I want to go back to work now and I don't want to feel high all day.' And so he kind of took that and, you know, talked to the attorneys and they said, well, why don't you extract from hemp And he knew extraction really well. So in mid 2016 I think they got a spray VAP and a few other little machines and started extracting CBD. Um there were four or five of them at the time, and then they had to figure out what to do with it. Right. so not only could they provide it to their friends and family, but they were producing enough where they needed to find a way to sell it. And so they put up a little Shopify website and one of the other original founders had an Instagram following for his extraction. And the cannabis industry said, 'Hey, we're going to sell some CBD and we really want to sell it to you, you know, the highest quality at an accessible price. And we want to provide third party test results,' which really wasn't a thing. In 2016, they put up a website and they did a hundred thousand dollars in sales in one weekend. Which was pretty incredible. And so I I came on right after that, the week after when they really knew that this thing could scale. And I came in a little skeptical to be honest, I never had heard of CBD. And about a month then the testimonials started coming in that what it has done for you know, people, their friends, their family, their children, and it was just overwhelming. And we really then took the bull by the horns from there and started putting significant effort into fulfilling our mission of, to get accessible CBD to everybody.

Kannaboom (05:49): What a great origin story. I mean, in agile terms, it was a minimally viable launch that proved itself. And then you guys do it up from there.

Chase Terwilliger (06:00): Yeah. I wish he could see the first website. It was definitely an MVP

Kannaboom (06:05): Well, and just then, the organic demand for it that you guys recognized and were able to service. So that's a great story. And I think you, you mentioned a couple of things there that are worthy of digging into, and one, you know, the quality there's, there's a lot of companies out there. I think I read the other day about 1,500 CBD companies and not a lot, well, zero real quality control. And the other thing is there's, we've seen the prices begin to come down, but I noticed early that your brand was a little more reasonably priced.

Chase Terwilliger (06:42): Yeah. So as far as quality there are 15 - you know, we have 1,500 with here, 3,000 CBD companies too. We know a lot of those are dying off right now just with the pandemic, unfortunately, but there's only a handful that I believe really comply by the quality standards that the FDA will put into place. It's very expensive to comply with those. It requires a whole quality department. But we've invested in that. We've also invested in science. You know, we're the only company that has generally recognized as safe self-affirming, generally recognized as safer you hear grass for all three of our ingredients, which are broad spectrum, full spectrum and isolate. Those are a hundred thousand plus dollar studies that we get reviewed by toxicologists ,third party toxicologists to make sure that our products are safe. You know, not many companies can say that. So we've really invested a lot in the quality you know, for our customers and to make sure that we're well positioned to win in the market in the future. As far as price points go. That was one of, king of the first things that the team before me did was say that, you know, we want to be a brand for the people. And you know, we, we started with the 'CBD movement' and we've actually trademarked that, but you know, you'll see it, if you come to our office ever it's everywhere. But really the start of this CBD movement, and one of the things was not only to provide a high quality product, not only be transparent about what's in our product but also provide it at an accessible price point. So in 2016, we have the same prices that we do today. So it was substantially lower. You know, now we've seen our competitors come down or get closer to where we're at. But at the time it was, there was a big, big delta there between our competition and ourselves.

Kannaboom (08:54): For a while it was mystifying why It would cost so much when it's an, it's an herb out of the ground, like oregano. So how could it, how could it be so expensive? You know, there's a lot of misconceptions and you mentioned people recognizing the value of medicinal marijuana, but not wanting to get high. And the fact that you can get just about all those benefits and you don't have to be intoxicated by that aspect. And then as you touched on, really, even though it is an herb out of the ground, there are still things, there can be pesticide and mold and heavy metals, and you do want to test it because you're putting this into your body.

Chase Terwilliger (09:31): Absolutely. I mean, that's, that's incredibly important and you wouldn't believe how many crops that we had that came in that did have high for pesticides or heavy metals that luckily, you know, we, we test from multiple labs too. That's another problem within the industry is that, you know, there's only so many reputable labs or at least there were but luckily we have that quality department, like there's no getting around it. It either passes a quality test or it doesn't. But yeah, it's a, it's a maturing industry and it's maturing quickly and hopefully FDA regulation will really push that agenda to even be a safer and better industry in the long run.

Kannaboom (10:17): And I know that process is unfolding and, you know, no one seems to know how long it will take, but there's a dire need for some regulation there. But one thing that caught my eye about your brand is that you are U.S Hemp Authority certified. From my understanding, they're taking kind of food-grade FDA regulations and applying them to the CBD market. Is that generally what's what's happening?

Chase Terwilliger (10:43): Yeah. Yep, exactly. So they wanted, you know, it was, it was kind of a subset of the Hemp Roundtable. That said, you know, we need to be able to separate the good actors and the bad actors, the ones that really care about the quality of the product. And you know, it is expensive to go through that process. But I also believe that they do sponsorships for smaller companies. Again, because we believe that, you know, the, the core mission is to get quality CBD to the people. And we know that if there are those bad actors out there, which there are, and they're not going through the same quality pro protocol that could slow down the industry and restrict access to people. And, you know, we believe in CBD and all the other minor cannabinoids and believe that it will improve quality of life. So long story short you know, the Hemp Authority really stepped in and put a rigorous protocol an audit around CBD companies, you know, all the way from where they get their hemp, and the testing, that goes into it their SOPs their safety procedures and any quality manual, they look through just every little thing how you're manufacturing it and make sure that it's it abides by the standards.

Kannaboom (12:10): Well, and I point my readers and listeners to a few select brands in their only U.S. Hemp Authority brands, because I'm not a scientist or a chemist. So I've kind of outsourced my trust function to these people, just the way you would with the Good Housekeeping Seal or the, the, the Underwriters Laboratories Seal on products. And, you know, I think it's really needed when there's upwards of, as you say, maybe 3,000 brands out there and some of them are fly by night. For sure.

Chase Terwilliger (12:38): Yeah. I just answered this for a friend of a friend over the weekend. He said, 'How do I know if I'm getting a good CBD product?' I said, 'Well, other than going to CBDistillery.Com, you know, you can just look for that orange seal. That's all you need to do. And you know that, and you can trust that that's a good product, so you're spot on. There you go.

Kannaboom (13:00): So as you referred to, you have full spectrum and broad spectrum and isolate, there are some companies in the space, I guess, you know, there are true believers in the entourage effect who don't provide the isolate. So what's your, what's your thinking in providing all three of those?

Chase Terwilliger (13:15): Yeah. so, you know, I personally believe in the entourage effect. You, you get the best, the best by far full spectrum is our, is our number-one seller. And you get the best benefits from that entourage effect. We had isolate and we still do have isolate. That was a product that was really made for the individuals who were concerned about having THC or even trace amounts of THC in their products. So they're willing to go with what we believe is somewhat of an inferior product to full spectrum, still a good product, great product. But I guess that's my personal, my personal opinion is that full spectrum's better. And they can get it without THC, now we introduced it within the last two months our broad because we finally got GRAS for a broad spectrum. And so we introduced a broad spectrum tinctures, which are slowly cannibalizing, our isolate tinctures which is exactly what we want. We want consumers you know, they may not get the THC portion, but they will get some of the other minor cannabinoids. Some of the terpenes that are also beneficial through our broad spectrum offering, but still have the ability to not have any THC in the product.

Kannaboom (14:36): Right. Some people still get drug tested, or they may have concerns. I mean, it's a negligible amount, right? It's 0.03%. But if somebody really wants to avoid it, an isolate would do that.

Chase Terwilliger (14:48): Exactly. and so you know, we, we provide that just in case people do have that concern.

Kannaboom (14:55): I don't think I've ever taken an isolate and, you know, I, I take a lot of CBD and I use balms and stuff. Do you think the efficacy is, is different with a pure molecule?

Chase Terwilliger (15:06): Yeah. So, and this is, what's going to be kind of the next chapter of CBD, other than regulation, will be these clinical studies because there's thousands of them, but none of them hone in on, you know, what's the difference, what's the effectiveness of isolate versus full spectrum. You know, personally, I like the full spectrum more, cause I think, like I said, like you said, there is that entourage effect, you know, it's anecdotal evidence there. In my personal opinion and I also enjoy the terpenes I believe that they have a relaxing effect as well. And that's why that's one of the things that kind of differs between brands is the terpene profile. One of the proprietary things that a brand can really dial into in the CBD world. But yeah, so I, but I can't say that, you know, I can point to a study to say this works better than the other

Kannaboom (15:58): With terpenes there's room for a lot of innovation. In fact, I noticed you guys were among the first with a, with a CBG product that I noticed. So talk about some of the possibilities there. This is a wide open field there's room for a lot of innovation yet, right?

Chase Terwilliger (16:14): Yeah, you're exactly right, Tom. It is completely wide open and it's, it's one of the things, you know, other than the research and the regulation that we get really excited about and kind of geek out to are all these other minor cannabinoids that we've been experimenting with you know, internally for the last few years and now, you know, they never penciled out. They were always so expensive to get out of extraction. And now especially with the abundance of hemp planted last year extractors are turning to extract some of the CBG CBN CVC, and we have access to it and we can make it at a price that's, you know, accessible to our consumer. You know, we hope to bring those prices down in the future, but right now it's still somewhat of an expensive input costs, but there is so much possibility there, you know, we'll really have to look to clinical studies in the future to see you know, provide the, the extra level of credibility to the products, but our you know, internal tests and some other scientific studies have shown, you know, for example, CBG, which was the first product that we launched. And you can expect to see a lot of other minor cannabinoids from us here in the near future, but CBG, you know, really helps with inflammation. So it's just more targeted than just having CBD. And you know, I believe our consumers too are somewhat of a different type of consumer that were there. We kind of call them cannabis connoisseurs, and so they really take to new minors and love to give us feedback on them. But there's, there's a whole new market for every single one of those. And it's going to be really exciting to see them start to play off, play out now that they're more accessible.

Kannaboom (18:09): Yeah. CBG is kind of the new kid on the block. And is there evidence that it's better anti-inflammatory than CBD?

Chase Terwilliger (18:17): So there are a number of studies out there that point to that. But you know, we haven't done any internally yet, and that's what we're working on as well.

Kannaboom (18:29): If you can, about your process for innovation. I mean the front end, there's a, there's a plant geneticist who is going to try to grow the cultivar that has an elevated level of this or that cannabinoid, a chemist is going to be involved. And then you're going to have a process engineer. And do you do market research ahead of time to try and find what the market wants or how do you go about developing a new product?

Chase Terwilliger (18:57): So for sake of conversation, the if, if you would have asked me that question two years ago, I would have said we just put it out and see what the consumer likes you know, and make sure it passes quality now as we've grown, we have a much stricter and longer process whether that's good or bad, I, I tend to think it's a good thing, but it does take us a little longer to come, go to market with a product, but it's about a six to eight month stage-gate process. You hit the nail on the head with a lot of you know, a lot of emphasis on looking at the market and making sure there is a market for it. You know, making sure that we can get it in an affordable way that we can pass that savings along to the consumer and that we're not going to get constrained supply wise in the future. And then there is an abundance of quality assurance and then an abundance of legal reviews. So legal reviews. I mean, you guys have probably talked about it on the show before, but label reviews labels, it's a nightmare for us because every state has different labeling requirements. You know, all of those things, even to the marketing launch plan to make sure that we're not, you know, making any claims that the FDA will get we'll get a letter from the FDA about it's just, it's a long process, a lot longer than it used to, which kind of stagnates innovation from time to time, which is frustrating. But at the same time, we're making a less risky business decision which is, is what we need to do. And we still ended up getting it to the end consumer and collecting their feedback and making it in iterations to the product from there. But yeah, it's, it's kind of a lengthy product process now.

Kannaboom (20:51): Yeah. Regulation is a double edge sword, I guess. Right. But I can see where being U.S. Hemp Authority certified means you do have these hoops to jump through, but as you do that, you're confident and your customers can be confident that you're providing a safe product. And in the end.

Chase Terwilliger (21:09): Absolutely.

Kannaboom (21:11): What excites you about this industry and about leading CBDistillery right now?

Chase Terwilliger (21:16): Yeah, I think it's, it's, I mean, what excites me the most about leading see, but it's still are in and you know, what motivates me to get out of bed every day is there's not many individuals that in many companies that can really be part of, of a movement and one that is improving the quality of life of so many every single day that goes by there's more people that are educated on CBD and have at least tried it. Some people don't get benefits, that's fine. But for the ones that do you've heard the testimonials, you take it. I mean, it's, it's a tremendous life change for them and to be able to provide that to them and that's something special and something that's exciting and this industry is just going to get larger and there's going to be more education which is really exciting for us, which means more people trying CBD. Um and there's going to be, you know, a higher basically de-stigmatizing of the plant which, you know, we continue to do on, on both the marijuana side and, and the hemp side, but that's been a big challenge for us. So that's really exciting. As I mentioned before, the minor cannabinoids now that we have access to those are, is going to be exciting, the research especially once FDA regulation hits, it'll just open the door to so much research that can go on and we can start to really dial in on certain dosages, which is a little challenging right now. And so that's, that's also exciting. And then it's just going to be really cool to see, you know, cannabis, product, ingestible, cannabis products sitting on mass retail shelves, you know, have it be part of everybody's everyday routine. That's exciting as well.

Kannaboom (23:17): I think we've come so far. One of my early, earlier guests was Keith Stroup who started NORML, the National Organization for the Reform of Marijuana Laws 50 years ago. And for a long time there wasn't much progress, but then when things up there in Colorado happened in and out in California, and boy we've come a long ways in the last decade in, in some ways I feel like it's just in time. I mean, right at this moment in history, we need CBD and cannabis more than, than we have in a long time. That's my belief. I mean, I think there's more people more stressed right now than we've seen in a long time.

Chase Terwilliger (23:55): Yup.

Kannaboom (23:55): You mentioned dosage that confuses a lot of people, because CBD can be subtle. I mean, it can be, if you're not really sick or it's not super clear what you're hoping for, in my experience, it can be a subtle sort of result. How do you tell people to find the correct dosage?

Chase Terwilliger (24:15): Yeah. And that's, that's challenging and something that we're working on, getting better at educating the consumer on exactly how much to take. What we recommend is that our, our, where we've seen the most benefit from individuals is really around that 30 milligram mark. And so our number-one seller is, is our 30 milligram per serving in each dropper really have them start there and then they can go up from there easily by taking the dropper and a half or two droppers. You know, we don't suggest more than two droppers. And then if it's, you know, some people do say it's too strong, they can take half a dropper, but really it's starting at that 30 milligram mark is where we've seen it. You know, if you were looking at a bell curve right in the middle and then there's just certain deviations off there.

Kannaboom (25:09): Yeah. So if you have like knee pain or something, that's fairly easy to judge if it's, if it's helping or not. Yeah.

Chase Terwilliger (25:16): Yeah. Those are great. And then our topical products also worked pretty well for really well for, for knee pain or back aches. And so sometimes we'll, we'll talk to a consumer and kind of switch them out, see if it works.

Kannaboom (25:32): So you were referring to sort of an enthusiastic customer base. Who, who are your customers? Are they athletes, are they aging? Are they concerned with inflammation? Do they take it as a daily preventative? Or what do you know about your customer?

Chase Terwilliger (25:46): Yeah. Yeah. Our demographic is really 45 plus. Now we have a number of 25 year olds obviously, and some others, you know, we see this, this younger group, that's really the cannabis connoisseurs that I mentioned earlier that have really helped us drive innovation are great sounding boards, cause they're very vocal on what they like and what they don't like. But when we look at our demographic and where we sell the most, it's split straight down the middle of male and female and it's 45 plus. And those are also the, that's also the group that is taking it more often. So, you know, I believe that our, our compared to the industry, you know, we have over 60% of our customers when we surveyed them that said that they take the product daily, which you can see a tremendous, if you, if you ask, you know, how effective is the product the people who take the product daily and and the ones that also understand the endocannabinoid system you know, they're, they're they're getting a lot more benefit out of the product.

Kannaboom (26:53): There's still a lot of education to be done, but when you talk about the endocannabinoid system and the whole notion of homeostasis and just achieving that kind of balance, maybe you aren't attacking a specific problem, but you're keeping your body well-tuned.

Chase Terwilliger (27:07): Exactly. That's why I take it every day and I can, I can truly feel the difference when I take it. And when I don't, because it's just a little more out of whack it really brings you back to homeostasis. And then, you know, as where I sit, I have to dig into the, to the education behind it. And and man, it is just really exciting and cool to read about how CBD interacts and other cannabinoids and natural occurring cannabinoids in your body interact with your physiology to, to push you back into homeostasis.

Kannaboom (27:43): 45 is when you're maybe just beginning with a little insomnia and the joints are a little creakier, there's a lot of compelling reasons as you age to kind of medicate with CBD.

Chase Terwilliger (27:54): Absolutely.

Kannaboom (27:55): Chase, what else should we cover that we haven't covered?

Chase Terwilliger (27:59): No, I think we touched on a lot of great things, you know, the quality aspect of the industry and how that's going to change the de-stigmatizing of hemp. We talked a little bit about the FDA, you know I think that that, that will help de-stigmatize like we saw this huge jump and at the end of 2018 with the 2018 Farm Bill, and because just, you know, the the passage of that bill gave so many consumers, the credibility for CBD that we needed and, and, you know, de-stigmatizing the plant to push them over. So, you know, I think if we think we've covered a lot so far, so I don't know. Is there anything else that you'd like to dig into?

Kannaboom (28:49): Well, one thing you just mentioned, the FDA, and I don't know if you have a feel, I mean, I don't know if the industry, my sense is the industry is beginning to get to the point where there's the things that other industries have lobbyists and trade organizations. Is there a feel within the industry for what's happening with the FDA and when to expect something? Is there frustration? I mean, it seems to me that they've kind of dragged their feet, but, but I don't know. Maybe that's just the pace at which they do everything.

Chase Terwilliger (29:15): Yeah. It's really hard to say if they drug their feet, you know, they obviously got hit with a worldwide pandemic in the middle of all this. I gotta give them a little, little credit there. But the industry desperately needs it. And so we're hoping one of, one of their kind of last sticking points is in the GW Pharmaceutical studies, which is a CBD product, but it's at very high dosages, much more than 30 milligrams a day. I think it's, it's something like five or 10 milligrams per kilogram of weight. So you're up into seven to 1,700 to a thousand milligram range. But with that, there were some liver enzymes, small amounts that showed up in some of their studies. So I think the FDA is just looking to make sure that at the levels that we're providing there aren't any liver enzymes. And that's actually, we're part of a study right now with Charlotte's Web and Kannaway and some other larger CBD companies that are looking at those liver toxicity levels in our product. And I think once we can provide them that along with some other other companies that are working on it as well, I would hope that they get more comfortable and can move forward with regulation. I mean, they know that we need it as well. And they have, they have the budget to do it. So we're hoping and hopeful for early next year that there's regulations in place, could be earlier. It could be later kind of a moving target, one of the many in this industry.

Kannaboom (30:55): Well, and like you said, there's, there's other stuff going on and, you know, and it's such an unusual circumstance. I mean, I think I've heard that normally bringing a drug to market takes 10 years and a billion dollars, and this isn't a typical quote unquote drug. It's an organic substance that people have used for thousands of years, but we're trying to productize it in a way that consumers can have confidence in the safety of it. And that might be a different beast for the FDA altogether. I don't know.

Chase Terwilliger (31:27): Right. It's extremely complicated because of the GW Pharmaceutical Epidiolex drug cause like you said, people have been using this for centuries. It just happened to be technically illegal. You know, before 2014.

Kannaboom (31:49): One more question about sort of the future of the industry of those 3,000 companies. A good percentage are probably going to fade away. No, one's got a crystal ball, but obviously we can, we can anticipate consolidation, probably some acquisitions and mergers and in the end, I don't know if it looks more like, you know, the alcohol industry or aspirin manufacturers, but what do you have any expectations for, you know, five years out?

Chase Terwilliger (32:16): Yeah, yeah. I mean, like you said, a lot of those smaller companies will end up folding, you know, there's going to be just like any of this industry, there's going to be a handful of brands that win. And who's the best position to do that. And we believe that we are. They'll undoubtedly be consolidation. We already saw it with Charlotte's web purchasing Abacus which is their CBD Medic brand. I believe the topical and I, I believe we're going to see more of that just cause it, it makes sense. You know, if you can kind of couple, some brands up with, with upstream capabilities with extraction you know, you can really have a powerful machine to move forward. So I think you hit the nail on the head with, with the consolidation in the industry, especially after the FDA regs come up.

Kannaboom (33:13): I don't want to ask you to give away too much, but is that part of your strategy?

Chase Terwilliger (33:18): Uh you know what it's, it's always always discussed within our organization is where are the opportunities? How can we fulfill our vision and mission of the company to get high-quality CBD at accessible prices to everybody and really be leaders of the CBD movement. And so if it falls into that and our strategy, then we're eyes wide open to any opportunities.

Kannaboom (33:44): Cool. Well, I'd like to add that listeners can get 15% off at CBDistillery with the coupon code Kboom at checkout, and like to ask where, where can we find you online?

Chase Terwilliger (33:57): Yeah, you can go to CBDistillery.com.

Kannaboom (34:01): And you guys are on Twitter and Facebook as well and Instagram.

Chase Terwilliger (34:05): Yep.

Kannaboom (34:06): We'll look for you there. Chase. Thanks so much for taking the time to talk about the brand and it really is an exciting time and I'm really pleased to be able to get the story from you and to tell our listeners about it. Thanks, Tom. I enjoyed talking about it.

Kannaboom (34:20): You've been listening to the Kannaboom podcast with host Tom Stacey. If you like the show and want to know more, please check us out at Kannaboom, with a K, dot com and please leave us a review at Apple podcasts or wherever you listen. See you next week.